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Abstract
The myth that patients with liver cirrhosis are “auto‐anticoagulated” is outdated, and 
evidence shows that these patients frequently experience thrombosis. Portal vein throm‐
bosis (PVT), although considered as rare, it gradually increases complications that are 
more likely to occur during late‐stage liver cirrhosis. The aim of this chapter is to perform 
a review of nonmalignant portal vein thrombosis in cirrhosis, in terms of prevalence, 
pathogenesis, diagnosis, clinical course, and management. Studies were identified by a 
search strategy using MEDLINE and EMBASE databases. For the MEDLINE search, we 
used the following terms: (“liver cirrhosis” [MeSH Terms] OR “cirrhosis” [All Fields] 
OR “cirrhosis” [All Fields]) AND (“portal vein” [MeSH Terms] OR “portal vein” [All 
Fields]) AND (“Thrombosis” [MeSH Terms]). For the EMBASE search, we used the fol‐
lowing terms: (cirrhosis OR phrase liver cirrhosis) AND (phrase thrombosis/OR phrase 
vein thrombosis/OR phrase thrombosis prevention/OR phrase portal vein thrombosis/
OR phrase liver vein thrombosis/OR phrase mesenteric vein thrombosis/OR thrombosis). 
Studies were considered eligible if they referred to any aspect of prevalence, pathophysi‐
ology, clinical presentation, diagnosis and management, or therapy of PVT in cirrhosis. 
We put forward possible responses to these unsettled issues starting with prevalence, 
pathogenesis, and treatment options.
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1. Introduction
Portal vein thrombosis (PVT) is frequently associated with cirrhosis, mostly in patients with 
advanced liver disease or hepatocellular carcinoma (HCC). The physiopathology of PVT 
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
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distribution, and reproduction in any medium, provided the original work is properly cited.
development is still under debate, and at the moment, there is a lot of controversy regarding 
the most efficient treatment. Moreover, the outcome in cirrhotics with PVT awaiting a liver 
transplant or the influence of thrombosis on posttransplant survival and morbidity is still 
unknown.
2. Epidemiology of portal vein thrombosis in liver cirrhosis
PVT is rarely diagnosed in the general population, the prevalence as reported by autopsy‐
based studies being up to 1% [1]. Genetic or acquired thrombophilia, mieloproliferative dis‐
eases, acute pancreatitis, acute cholecystitis, or other inflammations in the abdominal cavity 
are the main causes of noncirrhotic PVT [2].
In cirrhosis, PVT prevalence varies between 0.6 and 28% depending on the diagnostic method: 
imaging exam, during surgery for liver transplantation, or autopsy reports [3–5]. In the last 
years, PVT prevalence has increased as a result of the widespread use of imaging techniques, 
such as Doppler ultrasonography, computed tomography, or magnetic resonance, but its 
exact value is still not known. Studies based on ultrasonography results reported a preva‐
lence of 10–28% in cirrhotic patients, excluding those with HCC [2]. The prevalence of PVT in 
liver transplant candidates is similar to that in other cirrhotic patients with the same degree 
of liver disease, although MELD and Child‐Pugh scores were higher in patients with PVT, 
confirming the fact that PVT prevalence increases with the severity of liver cirrhosis. Thus, 
PVT prevalence is low (1%) in compensated liver cirrhosis and up to 28% in decompensated 
liver cirrhosis [6–8]. Association between liver cirrhosis and malignancies, especially HCC, 
may increase PVT prevalence up to 44% [6].
If data on the prevalence of PVT are frequently reported, those on the incidence, however, 
are quite scanty. Maruyama et al. in a retrospective analysis of 150 patients with cirrhosis, fol‐
lowed up for a median period of 66 months, reported a cumulative overall incidence of PVT 
of 12.8% at 1 year, 18.6% at 3 years, 20% at 5 years, and 38.7% at 8–10 years [9]. Moreover, the 
incidence of PVT in patients awaiting liver transplant was reported to be 7% after one‐year 
follow‐up [10].
3. Pathogenesis of portal vein thrombosis in cirrhosis
Pathogenesis of PVT in patients with cirrhosis still remains uncertain, although some authors 
consider PVT a complication of liver disease. However, its development is unpredictable and 
the risk factors are not well recognized. According to Virchow’s triad, venous thrombosis is 
the result of the coexistence of low blood flow, endothelial injury, and a hypercoagulable state. 
For these reasons, PVT in cirrhosis could be developing as a consequence of portal hyperten‐
sion, associated with endothelial dysfunction and a relative hypercoagulable state [11, 12].
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Portal hypertension is characterized by a reduced portal flow due to increased intrahepatic 
vascular resistance. This phenomenon is further increased as liver disease progresses [13], 
representing one of the risk factors that determine the increased incidence of PVT in advanced 
liver disease as compared to early compensated cirrhosis. This hypothesis was confirmed 
in one prospective study, which demonstrated that the reduced portal flow velocity below 
15 cm/s was the only independent variable correlated with the risk of developing PVT at 
1‐year follow‐up [13].
Advanced cirrhosis is associated with profound and complex coagulation defects, involving 
procoagulant and anticoagulant factors, fibrinolytic system, and platelets number and func‐
tion [12]. The net result of all of these defects may be a prothrombotic state, which is likely 
to be related with the increased endothelial synthesis of von Willebrand factor (vWf) and an 
increased level of factor VIII, combined with low levels of hepatic anticoagulation agents such 
as antithrombin III, protein C and S [14, 15].
A number of different inherited and acquired disorders have been also considered as predispos‐
ing factors for PVT in patients with cirrhosis, although with variable degree of evidence [16–18]. 
One study found antiphospholipids antibodies in more than half of cirrhotic patients with PVT 
[19], whereas variable association of newly recognized risk factors for inherited thrombosis 
such as the Q506 polymorphism in the gene coding for factor V or the G20210A change in the 
prothrombin gene (PTHR A20210) has been reported in patients with cirrhosis complicated by 
PVT [16, 20, 21]. None of these changes were confirmed as independent risk factors for PVT in 
liver cirrhosis. PAI‐1 4G‐4G and MTHFR 677TT screening of patients could be useful, especially 
in alcoholic or cryptogenic cirrhosis, to identify patients in which new drug therapies based on 
the inhibition of the hepatic stellate cell activation could be easily assessed [22].
Thrombocytopenia was considered for a long time a risk factor for bleeding in patients with 
liver cirrhosis, but recent reports did not confirm this hypothesis. Some studies showed 
abnormalities of platelet aggregation in patients with cirrhosis [23, 24], which was attributed 
to decreased serum levels of clotting factors [23], impaired production of thromboxane A2 
and arachidonic acid, or impairment in adhesion molecules [25, 26]. This theory was con‐
firmed by multiple electrode aggregometry, which demonstrated a decreased aggregation 
activity of platelets, although this phenomenon was not observed under stimulation by ris‐
tocetin. This finding implies that the cause of platelet hyporeactivity does not lie in defective 
transmembrane or postmembrane signaling pathway, while platelet activity was positively 
correlated with the number of platelets. Interestingly, platelet activity was significantly lower 
in the PVT group than in the non‐PVT group, although the platelet count was not significantly 
different in either group. A clear reason for this finding was not given, and it is suggested that 
adaptive changes in platelet function occur after the development of PVT [27]. Some studies 
consider the degree of thrombocytopenia to be an independent risk factor for PVT, which may 
seem paradoxical since low platelet count should logically predispose to bleeding. Possibly, 
as cirrhosis and portal hypertension progress, the resultant decrease in portal flow outweighs 
a protective effect of low platelet count against thrombosis [27].
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Another factor associated with PVT development in liver cirrhosis is endothelial dysfunction. 
Portal hypertension and inversion of portal vein flow are among the factors associated with endo‐
thelial dysfunction. Endotoxemia is another factor that contributes to endothelial dysfunction in 
cirrhotic patients with PVT. The biological consequences of systemic endotoxemia are low‐grade 
inflammation and peripheral vasodilatation [27]. In vitro studies have revealed that lipopoly‐
saccharides, even in low concentrations, may stimulate vWf release from the endothelium [14]. 
Moreover, Violi et al. provided evidence of a direct correlation between endotoxemia and the 
ongoing prothrombotic state in the portal venous system [28]. Therefore, it is plausible that endo‐
toxemia, in combination with the coexisting increased vWf release frequently found in cirrhosis, 
together with portal hypertension may trigger prothrombotic mechanisms, the development of 
endotoxemia being a surrogate marker of disease severity in patients with cirrhosis [29].
Besides the common risk factors for PVT, other predisposing conditions such as variceal 
sclerotherapy, liver malignancy, abdominal surgery, or sepsis were described. The roles of 
sclerotherapy and cyanoacrylate glue injection as potential trigger factors for PVT are contro‐
versial, but they were reported in the literature [30]. Such associations could occur as a result 
of selection bias in patients with more severe portal hypertension. Surgical procedures for 
portal hypertension were also associated with an increased incidence of PVT [31, 32]. Among 
them, pericardial devascularization with splenectomy, and splenorenal shunts are associated 
with an increased risk of PVT [33].
Along with the sluggish portal flow [19] and the presence of liver malignancies (i.e., hepato‐
cellular carcinoma), other acquired local (abdominal surgery, trauma or bacterial infection, 
and portacaval shunts), or general (sepsis and myeloproliferative disorders) factors have been 
claimed as possible causes of PVT in patients with liver cirrhosis [12–16].
The main consequences of PVT are related to the extension of the thrombus and include intes‐
tinal ischemia and acute/chronic portal hypertension. Gastrointestinal bleeding due to portal 
hypertension following PVT has been reported as a major cause of death in patients with 
cirrhosis [34]. The pathogenesis of PVT in such patients remains unclear, although decreased 
portal vein blood flow, a hypercoagulable state, and systemic inflammation may be of impor‐
tance. Despite the great number of risk factors for PVT in liver cirrhosis, thrombosis itself 
should be considered a multifactorial disease, and the likelihood of developing PVT increases 
in direct proportion to the number of risk factors present in each patient.
4. Diagnosis of portal vein thrombosis
PVT diagnosis in cirrhotic patients involves clinical suspicion with further imagistic confir‐
mation. According to the moment of diagnosis, this particular type of venous thrombosis 
could be classified as:
• acute: sudden formation of a thrombus within the portal vein, with or without involvement 
of the mesenteric and/or splenic vein [35];
• chronic: the obstructed portal vein is replaced by collateral veins bypassing the thrombosed 
vein [36].
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4.1. Clinical presentation
PVT is frequently diagnosed in asymptomatic cirrhotic patients by routine abdominal ultra‐
sound (US). In most of these cases, PVT is chronic with partial obstruction. Acute partial or 
total PVT is frequently symptomatic, and it is associated with decompensation or further 
decompensation of liver disease.
The symptoms and signs of acute PVT could be represented by severe abdominal or lumbar 
pain with sudden onset, progressive over days, without peritoneal signs when the superior 
mesenteric vein is involved, functional ileus, ascites, or variceal bleeding. The majority of the 
patients with acute PVT associate systemic inflammatory response syndrome in the absence 
of sepsis. If the symptoms are not resolved in 5–7 days or liver cirrhosis is complicated by fur‐
ther decompensation and clinical deterioration, mesenteric vein involvement with complete 
loss of blood flow should be suspected.
Chronic PVT is asymptomatic in most cases. The pain is a sign of mesenteric vein thrombosis 
and bowel ischemia. Although there is a minimal change in the hepatic arterial blood supply, 
the portal pressure is increased, with the development of portosystemic collaterals and an 
increased risk of variceal bleeding. This fact supports the Baveno VI recommendations stating 
that it is mandatory to perform screening endoscopy in all patients diagnosed with chronic 
PVT within 6 months from the acute episode if a complete recanalization of thrombosis is not 
achieved [36]. A total of 22% of patients without varices at initial endoscopy will develop this 
condition in 3 years [37]. Therefore, a follow‐up endoscopy should be performed in subjects 
without varices at the baseline [36].
With regard to primary prevention of bleeding, no randomized controlled trial compared the 
effectiveness of nonselective beta‐blockers versus endoscopic band ligation in PVT. In this 
scenario, as well as in the context of the acute bleeding and secondary prophylaxis, Baveno 
VI recommends following the guidelines on PH in cirrhosis [36]. Besides prehepatic portal 
hypertension, portal cholangiopathy is another context associated with chronic PVT. Patients 
develop jaundice, abdominal pain, and episodes of cholangitis.
4.2. Imaging evaluation: abdominal ultrasound
When PVT is suspected, ultrasound is the first‐line imaging method to be used, since it holds 
an accuracy ranging from 88 to 98% for the detection of PVT with a sensitivity and specific‐
ity of 80–100% in the majority of studies [38, 39]. The sensitivity of ultrasound is particu‐
larly high in complete PVT, while the risk of false‐negative results occurs only in incomplete 
PVT [40] and isolated superior mesenteric vein thrombosis [38]. In two‐dimensional (2‐D) 
Gray‐Scale ultrasonography, a thrombus appears as a hypo/isoechoic material occupying part 
of (partial thrombosis) or the entire vessel (complete thrombosis). The normal portal vein can 
be eventually replaced by multiple tortuous vessels with hepatopetal flow, a condition named 
as “cavernomatous transformation” or “cavernoma,” easily detected with Doppler ultra‐
sound. Color/power and pulsed Doppler should be mandatorily used to confirm whether the 
vessel has a remnant blood flow, to help differentiate high‐degree partial thrombosis from 
complete thrombosis. The reliability of ultrasonography in the detection of PVT improves 
with the operator’s experience, and whenever PVT is clinically suspected, ultrasonography 
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should be performed by experienced operators [41]. Ultrasonography suffers from other limi‐
tations such as reduced visualization in obese individuals and in case of abundant bowel gas, 
and impossibility to assess bowel ischemia. This should be suspected in case of ascites and/
or high blood lactate levels. Ultrasound is sufficient to diagnose PVT in patients with a good 
acoustic window, but when ultrasonography is insufficient, a second‐line cross‐sectional 
imaging method should be considered to confirm or exclude the diagnosis.
4.3. Imaging evaluation: computed tomography and magnetic resonance
Contrast‐enhanced four phase (pre‐contrast, arterial, portal, and late) CT (CECT) and con‐
trast‐enhanced MRI (CEMRI) can be used, with CT is preferred in unstable patients with 
acute abdominal symptoms. Advantages of MR and CT over US include the possibility of 
detecting bowel ischemia, septic foci and intraabdominal malignancies, and higher sensitiv‐
ity in the detection of thrombosis in the splenic and superior mesenteric vein. Among the 
well‐known drawbacks of CT are exposure to ionizing radiation, the risk of allergic reac‐
tions, and nephrotoxicity. CEMRI is also contraindicated in patients with acute renal failure 
because of the risk of nephrogenic systemic fibrosis. Once PVT is diagnosed, CECT or CEMRI 
is mandatory to evaluate the extent of thrombosis and to allow a detailed mapping of porto‐
systemic collaterals, crucial to the planning of interventions aimed at recanalizing the portal 
venous system. It should be considered that clinical consequences of PVT mainly depend 
on the number of vessels completely occluded [42], as well as the degree of collateralization 
in chronic cases. Furthermore, the presence of ascites is a predictor of the lack of response 
to anticoagulation and should be reported [42]. Several classification/staging systems have 
been developed, but they rely heavily on anatomical considerations. The most commonly 
cited and used in clinical trials is the one proposed by Yerdel et al. [43]. However, there is no 
validated classification to be used in clinical practice in order to personalize risk assessment 
and guide therapy [44].
Both Doppler ultrasonography and multiphasic‐computed tomography have high sensi‐
tivity and specificity for PVT detection [45]. Doppler US is highly accurate in detecting 
thrombosis involving the trunk of the portal vein and intrahepatic branches, also providing 
additional information regarding the portal flow and its direction. CT is better at assess‐
ing the superior mesenteric vein, spontaneous portosystemic shunts, renal veins, and the 
inferior vena cava. While a CT exam is generally performed at the time of initial evalua‐
tion for liver transplant, Doppler ultrasound is appropriate for follow‐up imaging as it can 
be performed repetitively and does not have the risks of intravenous iodine contrast and 
radiation.
4.4. Imaging evaluation: malignant versus nonmalignant PVT
Patients with cirrhosis or neoplastic disease may develop either benign or malignant PVT. 
In patients with HCC, it is essential to radiologically distinguish tumor invasion of the main 
trunk or the branches of the portal vein as the cause for PVT versus bland thrombus in the 
portal vein because this could determine the proper therapeutic approach and their prognosis. 
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This is not without implications since the major vascular tumoral invasion is an absolute con‐
traindication to transplant, while bland PVT in the presence of HCC needs to be approached 
similarly to a non‐HCC setting [45]. Tumor‐related PVT is usually detected in portal vein 
branches adjacent to and in direct continuity of the tumor, and is often associated with a high 
alpha‐fetoprotein level.
Until recently, imaging differentiation of the benign from the malignant PVT has depended on 
the findings of contrast enhancement and luminal expansion on abdominal ultrasound, CT, 
or MRI. Signs of malignant PVT on ultrasound include an expansive aspect mass inside the 
lumen, with heterogeneous aspect and disruption of portal vein walls. Color/power‐Doppler 
ultrasound shows signs of neovascularization within the mass, and pulsed Doppler could 
confirm arterial flow with a high resistance index associated with malignant PVT. One of the 
most sensitive and with small additionally methods for malignant PVT diagnosis is contrast 
ultrasound. In contrast to bland PVT, which remains unenhanced in all phases, a malignant 
PVT shows the same contrast‐behavior as HCC—rapid wash‐out (hypoperfusion in compari‐
son to the rest of the liver parenchyma) in the portal/late phase.
Enhancement or an increase in density or intensity on CT or MRI, respectively, after con‐
trast administration could also establish the diagnosis of malignant PVT. Conversely, absent 
enhancement confirms bland thrombus.
Careful screening for PVT is important in all patients with cirrhosis and in those under eval‐
uation for liver transplantation. Repeated imaging at specified intervals—usually every 3 
months, during the pretransplant waiting period—is also recommended in order to detect 
thrombosis that may develop during follow‐up [7]. Patients who develop unexplained wors‐
ening of liver functions or gastrointestinal bleeding despite adequate prophylaxis should also 
be evaluated for PVT of recent onset.
5. Management of portal vein thrombosis
Nowadays, there are two main possibilities of PVT treatment: anticoagulation with low‐
molecular‐weight heparin (LMWH) or oral anticoagulants, and transjugular intrahepatic por‐
tosystemic shunt (TIPS). The best therapeutic solution is still under debate, but the final goal 
is to prevent PVT extension to the mesenteric veins and achieve PVT recanalization (Figure 1).
5.1. Anticoagulant treatment for PVT in cirrhotic patients
Anticoagulant treatment in cirrhotic patients who are not on a liver transplant list may be 
considered if the superior mesenteric vein is involved or the patient carries a known pro‐
thrombotic condition [36].
Some studies have reported that spontaneous recanalization of the portal vein in the absence 
of an anticoagulant treatment is unusual. In the study by Francoz et al., no patient achieved 
recanalization in the absence of anticoagulation, while 42% achieved recanalization while 
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under anticoagulant therapy [46]. Senzolo et al. reported thrombus progression in 75% of 
patients who did not receive anticoagulant treatment, compared to only 15% of treated 
patients [47].
There are limited studies reporting on the use of anticoagulation for PVT in patients with 
cirrhosis. In all these studies, complete recanalization has been described in 33–45% of cases, 
while partial portal vein recanalization was observed in 15–35% of cases [46, 48, 49]. In a 
study by Senzolo et al., prospectively enrolling 56 individuals (35 treated and 21 controls), 
complete recanalization was achieved in 36% of subjects and partial recanalization in 27%, 
after therapy with LMWH (mean 5.5 months) [47]. The time between diagnosis and antico‐
agulation—under 6 months—was the most important factor positively associated with portal 
vein recanalization. In a study from Spain, by Delgado et al., including 55 cirrhotic patients, 
the majority of them (75%) diagnosed with partial PVT, complete portal vein recanalization 
was achieved in 45% of cases after a median duration of therapy of 6.3 months with vitamin 
K antagonists (VKA) or LMWH [48]. In this study, the only predictive factor for achieving 
complete portal vein recanalization was also early initiation of anticoagulation therapy after 
diagnosis, in less than 14 days.
Clinical suspicion of 
PVT











LT candidates and trunk 






No ancoagulaon Ancoagulaon PVT progression TIPS
YES NO
Figure 1. Algorithm for the diagnosis and management of PVT in liver cirrhosis.
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Nowadays, there are no clear data regarding the duration of anticoagulant treatment, although 
Amitrano et al. treated 28 patients with LMWH and demonstrated that after 6 months, com‐
plete portal vein recanalization was achieved in 33% of cases and partial portal vein recana‐
lization was observed in 50%. In individuals with partial response to therapy, anticoagulant 
treatment was continued for more than 6 months, and 86% of these patients achieved com‐
plete recanalization [50].
The rate of PVT recanalization depends not only on the time of PVT diagnosis, but also on the 
type of PVT in most of the cases: complete or partial, tumoral or nontumoral. As shown by 
most studies, recanalization is uncommon in patients with complete thrombosis, but anticoag‐
ulation is still indicated in order to prevent the extension of the thrombus [46–50]. However, it 
is unclear what proportion of these patients would have recanalized spontaneously and, more 
importantly, whether they derived any clinical benefit from anticoagulation. This hypothesis 
was raised by other studies with conflicting results. Maruyama et al. reported a spontane‐
ous improvement in 47.6%, unchanged appearance in 45.2%, and progression in only 7.2%. 
There was no significant difference in the natural course of thrombosis, based on the degree of 
obstruction or the location of the thrombus, and recurrence of PVT after spontaneous resolu‐
tion was observed in 21.4% [9]. Our data also confirmed Maruyama’s study results. We dem‐
onstrated that in most of the cirrhotic patients diagnosed with PVT, the thrombus remained 
with the same dimensions or disappeared without any therapeutical intervention [51].
For cirrhotic patients diagnosed with PVT awaiting for a liver transplant, it is important to 
achieve recanalization and thus achieve a physiological portal vein anastomosis in order to 
ensure portal flow to the graft. Transplanting patients with PVT extended to the superior 
mesenteric vein or with extensive portal vein thrombosis is associated with higher morbidity 
and mortality, PVT being a predictor of posttransplant mortality in some studies [43, 52, 53].
An important objective in the management of PVT in cirrhotic patients awaiting liver trans‐
plantation is to achieve recanalization for the end‐to‐end portal vein anastomosis to be surgi‐
cally possible. Another objective is to prevent extension of the thrombus to the splenic and 
superior mesenteric vein, since these veins can also be used to restore portal flow to the graft in 
case the main portal vein is thrombosed. In the event that neither the portal vein nor the supe‐
rior mesenteric vein can be used, nonanatomical techniques to restore portal flow are possible, 
but these are associated with increased morbidity and mortality. Francoz et al. compared 19 
individuals with cirrhosis and PVT on the waiting list for liver transplantation who received 
anticoagulation therapy (VKA) with 10 individuals not receiving therapy. A total of 42% of 
treated individuals achieved complete PV recanalization. None of the untreated patients had 
recanalization, and, in fact, PVT progressed in 60 % in the untreated group. Moreover, antico‐
agulation therapy did not increase blood loss during liver transplantation [46].
The rationale for treating PVT in patients with cirrhosis is that it increases morbidity compared 
to matched cirrhotics without PVT, although there is controversy regarding the influence of PVT 
on the natural course of liver cirrhosis. PVT has been reported to be independently associated 
with a higher risk of failure in controlling acute variceal bleeding as well as rebleeding [44]. The 
occurrence of PVT has also been shown to increase mortality, which has been observed even 
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in patients with lower Child‐Pugh scores [46]. Recanalization of PVT has also been reported to 
reduce esophageal variceal pressure, improving morbidity, and mortality rates [44].
There are no clear recommendations for an optimal anticoagulation regimen for the treatment 
of PVT in patients with cirrhosis. Monitoring of anticoagulation regimen is complex in the 
cirrhotic patient and, therefore, choosing between different anticoagulants (LMWH, VKA, or 
the new oral anticoagulants) is a difficult decision. LMWH is less practical for patients, since it 
necessitates daily subcutaneous injections, although it does not affect INR values and, conse‐
quently, does not interfere with MELD or Child scoring. There is, however, limited informa‐
tion on the pharmacodynamic profile of LMWH in cirrhotic individuals.
Cirrhotic patients often have an increased volume of distribution because of fluid overload, 
and this makes it difficult to determine the optimal dose of LMWH. Moreover, the major route 
of elimination of the LMWH is through the kidneys, and, since many patients with cirrhosis 
have renal insufficiency, the half‐life of LMWH is increased. The only method of LMWH 
treatment monitoring validated until known is by determining the anti‐Xa activity, but this 
method is unreliable in cirrhosis [35, 55].
The primary problem with VKA is determining the adequate anticoagulation in patient with 
cirrhosis who already has an altered abnormal prothrombin time. Most studies have targeted 
an INR of 2–3 [54]. Based on an empirical experience not relying on randomized studies, if the 
baseline INR is over 2, it is difficult to determine if a given dose of VKA ensures adequate anti‐
coagulation. It may also be difficult to determine the optimal INR target for dose adjustment. 
There is also a potential risk of further lowering of protein C levels with the use of VKA, and 
this could theoretically increase the prothrombotic imbalance of individuals with cirrhosis.
The new oral anticoagulants—thrombin inhibitors and inhibitors of activated factor X such as 
dabigatran and rivaroxaban—offer the advantage of oral administration, the absence of labo‐
ratory monitoring, and an antithrombin‐independent mechanism of action [54]. However, 
there are a few reports regarding their use in cirrhotic patients, most of them isolated cases. 
One of the major disadvantages of these new anticoagulants was the absence of an antidote. 
This problem was solved for dabigratan and also for rivaroxaban, which could be the new 
class of anticoagulants preferred in PVT treatment. In cirrhotic patients, it may be necessary 
to reverse anticoagulation during episodes of inadvertent bleeding or at the time of surgery. 
While the effect of VKA can be expertly reversed by fresh‐frozen plasma or prothrombin com‐
plex concentrate, there is no potent and rapidly acting antidote to reverse the effect of LMWH 
or the newer thrombin inhibitors.
Even if the anticoagulant treatment seems to be the same in patients with liver cirrhosis, it is 
uncertain whether it is beneficial to anticoagulate asymptomatic patients who are detected 
with PVT incidentally on imaging [35, 55].
The impact of PVT on the natural history of cirrhosis remains a matter of great debate, and the 
clinical benefits of PV recanalization have fully demonstrated [50]. Despite this, there is evi‐
dence that cirrhotic individuals with PVT awaiting for liver transplantation should be treated 
with anticoagulation therapy because complete or partial portal vein recanalization has been 
associated with a better 2‐year survival rate after liver transplantation (82–83%) compared to 
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individuals with complete PVT (50%) [46]. Other situations where anticoagulation is expected 
to be beneficial are cirrhotic patients with acute PVT with extension to the superior mesenteric 
vein [35, 55]. Cirrhotic patients with well‐documented prothrombotic disorder should obvi‐
ously be considered for anticoagulation. Patients with cavernomatous transformation of the 
portal vein have been excluded from most trials since such patients are not expected to benefit 
from anticoagulation.
5.2. TIPS and thrombolysis for PVT in cirrhotic patients
The use of transjugular intrahepatic portosystemic shunt (TIPS) has also been reported to recana‐
lize the portal vein and also prevent rethrombosis by restoring portal flow through the shunt [56–
59]. TIPS insertion and recanalization is associated with mechanical thrombectomy. However, in 
such cases, TIPS is expected to be technically challenging with a higher failure rate and should 
be attempted only in experienced centers. Systemic or in situ thrombolysis has been reported in 
cirrhotic patients with PVT [60]. In noncirrhotic patients with acute PVT, rates of recanalization 
have been dismal with attempted thrombolysis. There has also been a high incidence of major 
bleeding [60]. There are no data to support this option in this setting. TIPS promotes the dis‐
solution or decrease in PVT, splenic, or mesenteric veins, in the US population of patients with 
predominantly compensated liver cirrhosis of various etiologies [57, 58].
6. Portal vein thrombosis and liver transplantation
Most of the studies on liver transplant patients with PVT revealed higher technical difficulties 
and mortality, postoperative complications, in the PVT group compared with those without 
PVT. The higher morbidity and mortality is multifactorial and is related to a more complex 
surgical procedure, increased requirement of blood transfusions, higher risk of complica‐
tions such as primary nonfunction or dysfunction, hepatic artery thrombosis, postoperative 
pancreatitis, sepsis, or renal failure [61, 62]. Moreover, there is a high risk of 9–42% of PVT 
rethrombosis [63]. Patients with Child‐Pugh class C cirrhosis, complete PVT, and alcoholic 
etiology of hepatic disease have a higher risk of PVT rethrombosis after liver transplant. Of a 
pooled total of 169 patients with partial PVT, 7 (4%) developed rethrombosis in contrast with 
14 of 114 patients with complete PVT (12.3%) [63].
The main treatment indication is early anticoagulation with low‐molecular‐weight heparin 
unless it is contraindicated for surgical reasons, although randomized controlled trials are 
lacking. Moreover, there is no consensus on how long anticoagulation should be continued 
posttransplant. In the absence of prothrombotic state, there is no evidence that pretransplant 
PVT justifies long‐term anticoagulation posttransplantation. Mortality is related to the grade 
of preoperative PVT. The 30‐day mortality in patients undergoing liver transplantation with 
or without PVT has been reported as 10.5% versus 7.7%, respectively [63]. The 1‐year mortal‐
ity was also reported to be significantly higher in a systematic review according to the pres‐
ence (18.8%) or absence (15.3%) of PVT [63]. The 30‐day mortality has been reported to vary 
between 3.8% for grade 1 and 2 PVT, and going up to 27% for grade 4 PVT [64]. Preoperative 
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PVT seems to influence early outcome more than long‐term results, with the maximum 
decrease in survival occurring in the first year, and medium‐term results with or without PVT 
appearing to be comparable if early mortality is excluded [65].
For many years, PVT had been considered as an absolute contraindication to liver transplanta‐
tion [66]. The first successful surgery for complete PVT was reported by Shaw et al. in 1985 [66]. 
Nowadays, the innovations in surgical techniques have made it possible to overcome problems 
due to PVT during transplantation. The stage of liver disease and the collateral circulation 
increase the complexity of surgical techniques and pose a challenge for the surgery, because it 
is very important to have an adequate portal inflow of the graft to maintain the liver function.
In order to establish if the patient has a surgical indication, preoperative assessment must 
evaluate the correct stage and grade of PVT based on a spiral CT scan or a magnetic resonance 
venogram. For surgical purposes, Yerdel et al. have classified PVT into four grades [43]:
Grade 1: Partially thrombosed portal vein, where the thrombus occupies less than 50% 
of the lumen.
Grade 2: More than 50% occlusion of the portal vein, including total occlusions, with or 
without extension into the superior mesenteric vein.
Grade 3: Complete thrombosis of both the portal vein and the proximal superior mes‐
enteric vein.
Grade 4: Complete thrombosis of the portal vein, proximal, and distal superior mesen‐
teric vein.
There are several available surgical techniques for PVT reconstruction during liver transplant 
surgery. All the techniques vary according to the degree and the anatomical spread of the 
PVT [65].
1. Portal vein thrombectomy (for Yerdel grade 1 and 2 PVT) and direct anastomosis of donor 
and recipient portal vein. A recent study suggested that 75–90% of transplants performed 
in patients with PVT, and the thrombosis could be managed only by thrombectomy [61]. 
After completion of the thrombectomy, adequate flow in the recipient portal vein or supe‐
rior mesenteric vein must be confirmed by releasing the vascular clamp before proceeding 
with the anastomosis.
2. In cases of Yerdel grade 2 or grade 3 occlusions, an anastomosis may be required between the 
graft portal vein and the recipient superior mesenteric vein. The anastomosis uses a section of 
the donor iliac vein as a graft. The presence of a large collateral vein may provide an alterna‐
tive portal inflow, although extraanatomical vessels are more fragile and prone to thrombosis.
3. Arterialization of the portal vein: anastomosis of the graft portal vein to the recipient arte‐
rial inflow.
4. Portacaval hemitransposition: an anastomosis of the graft portal vein is made to the supra‐
renal recipient inferior vena cava. The disadvantage of classic portacaval  hemitransposition 
Liver Cirrhosis - Update and Current Challenges166
is the persistence of portal hypertension associated with an increased risk of bleeding from 
gastroesophageal varices, which may occur in up to 50% of such cases [65].
Rodriguez‐Castro, in a systematic review, reported that among 49 patients with portacaval 
hemitransposition, 20% had episodes of variceal bleeding, 58% had persistent ascites, and 
26% presented with renal dysfunction after liver transplantation [66]. An alternative to porta‐
caval hemitransposition is renoportal transposition, where the recipient portal vein is anasto‐
mosed to the left renal vein [65].
7. Conclusion
PVT is a highly heterogeneous entity regarding its underlying risk factors and the association 
with liver cirrhosis independently of the disease stage. Although significant advances have 
been made in the field of PVT associated with liver cirrhosis in recent years, many important 
questions still remain unanswered. Most critical issue that requires future studies is the influ‐
ence of PVT on natural course of liver cirrhosis according to the new classification, and it has 
to establish the risk‐benefit ratio of anticoagulant treatment in different groups of patients, 
including the role of the new oral anticoagulant.
Abbreviations
Author details
Anca Trifan1,2*, Carol Stanciu2 and Irina Girleanu1,2
*Address all correspondence to: ancatrifan@yahoo.com
1 “Grigore T. Popa” University of Medicine and Pharmacy, Iaşi, Romania
2 Institute of Gastroenterology and Hepatology, Iaşi, Romania
PVT Portal vein thrombosis
LT Liver transplant
CT Computed tomography
MRI Magnetic resonance imaging
BB Beta‐blockers
TIPS Transjugular portosystemic shunt
HCC Hepatocellular carcinoma




[1] Kumar A, Sharma P, Arora A. Review article: Portal vein obstruction‐epidemiology, 
pathogenesis, natural history, prognosis and treatment. Alimentary Pharmacology & 
Therapeutics. 2015;41:276‐292
[2] Tsochatzis EA, Senzolo M, Germani G, et al. Systematic review: Portal vein thrombosis 
in cirrhosis. Alimentary Pharmacology & Therapeutics. 2010;31:366‐374
[3] Blachier M, Leleu H, Peck‐Radosavljevic M, et al. The burden of liver disease in Europe: 
A review of available epidemiological data. Journal of Hepatology. 2013;58:593‐608
[4] Amitrano L, Guardascione MA, Brancaccio V, et al. Risk factors and clinical presenta‐
tion of portal vein thrombosis in patients with liver cirrhosis. Journal of Hepatology. 
2004;40:736‐741
[5] Nery F, Chevret S, Condat B, et al. Causes and consequences of portal vein thrombosis in 
1,243 patients with cirrhosis: Results of a longitudinal study. Hepatology. 2015;61:660‐667
[6] Raja K, Jacob M, Asthana S. Portal vein thrombosis in cirrhosis. Journal of Clinical and 
Experimental Hepatology. 2014;4:320‐331
[7] Francoz C, Valla D, Durand F. Portal vein thrombosis, cirrhosis, and liver transplanta‐
tion. Journal of Hepatology. 2012;57:203‐212
[8] Kinjo N, Kawanaka H, Akahoshi T, et al. Portal vein thrombosis in liver cirrhosis. World 
Journal of Hepatology. 2014;6:64‐71
[9] Maruyama H, Okugawa H, Takahashi M, Yokosuka O. De novo portal vein thrombosis 
non virus‐related cirrhosis: Predictive factors and long‐term outcomes. The American 
Journal of Gastroenterology. 2013;108(4):568‐574
[10] Cagin IF, Atayan Y, Erdogan MA et al. Incidence and clinical presentation of portal vein 
thrombosis in cirrhotic patients. Hepatobiliary & Pancreatic Diseases International. 
2016;15:499‐503
[11] Primignani M. Portal vein thrombosis, revisited. Digestive and Liver Disease. 2010;42: 
163‐170
[12] Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. The New England 
Journal of Medicine. 2011;365(2):147‐156
[13] Zocco MA, Di Stasio E, De Cristofaro R, et al. Thrombotic risk factors in patients with 
liver cirrhosis: Correlation with MELD scoring system and portal vein thrombosis devel‐
opment. Journal of Hepatology. 2009;51:682‐689
[14] Ferro D, Quintarelli C, Lattuada A, et al. High plasma levels of von Willebrand fac‐
tor as a marker of endothelial perturbation in cirrhosis: Relationship to endotoxemia. 
Hepatology. 1996;23:1377‐1383
Liver Cirrhosis - Update and Current Challenges168
[15] Tripodi A, nstee QM, Soogaard KK, et al. Hypercoagulability in cirrhosis: Causes and 
consequences. Journal of Thrombosis and Haemostasis. 2011;9(9):1715‐1723
[16] Amitrano L, Brancaccio V, Guardascione MA, et al. Inherited coagulation disorders in 
cirrhotic patients with portal vein thrombosis. Hepatology. 2000;31:345‐348
[17] Dentali F, Galli M, Gianni M, et al Inherited thrombophilic abnormalities and risk of 
portal vein thrombosis. A meta‐analysis. Journal of Thrombosis and Haemostasis. 
2008;99:675‐682
[18] Tripodi A, Primignani M, Lemma L, et al. Evidence that low protein C contributes to the 
procoagulant imbalance in cirrhosis. Journal of Hepatology. 2013;59:265‐270
[19] Amitrano L, Ames PR, Guardascione MA, et al. Antiphospholipid antibodies and 
antiphospholipid syndrome: Role in portal vein thrombosis in patients with and with‐
out liver cirrhosis. Clinical and Applied Thrombosis/Hemostasis. 2011;17:367‐370
[20] Qi X, Ren W, De Stefano V, Fan D. Associations of coagulation Factor V Leiden and 
prothrombin G20210A mutations with Budd‐Chiari syndrome and portal vein thrombo‐
sis: A systematic review and meta‐analysis. Clinical Gastroenterology and Hepatology. 
2014;12(11):1801‐12.e7
[21] Janssen HL, Meinardi JR, Vleggaar FP, et al. Factor V Leiden mutation, prothrom‐
bin gene mutation, and deficiencies in coagulation inhibitors associated with Budd‐
Chiari syndrome and portal vein thrombosis: Results of a case‐control study. Blood. 
2000;96:2364‐2368
[22] D<Amico M, Pasta F, Pasta L. Thrombophilic genetic factors PAI‐1 4G‐4G and MTHFR 
677TT as risk factors of alcohol, cryptogenic liver cirrhosis and portal vein thrombosis, 
in a Caucasian population. Gene. 2015;568:85‐88
[23] Northup PG, Sundaram V, Fallon MB, et al. Hypercoagulation and thormbophilia in 
liverdisease. Journal of Thrombosis and Haemostasis. 2008;6:2‐9
[24] Ikura Y, Nakamichi T, Matsumoto S, et al. Hepatic aggregation of activated platelets con‐
tributes to the development of thrombocytopenia in cirrhosis. Hepatology. 2010;52:895A
[25] Laffi G, La Villa G, Pinzani M, Ciabattoni G, et al. Altered renal and platelet arachidonic 
acid metabolism in cirrhosis. Gastroenterology. 1986;90:274‐282
[26] Laffi G, Cominelli F, Ruggiero M, et al. Altered platelet function in cirrhosis the liver: 
Impairment of inositol lipid and arachidonic acid metabolism in response to agonists. 
Hepatology. 1988;8:1620‐1626
[27] Wosiewicz P, Zorniak M, Hartleb M et al. Portal vein thrombosis in cirrhosis is not 
associated with intestinal barrier disruption or increased platelet aggregability. Blood. 
2016;40:722‐729
[28] Violi F, Ferro D, Basili S, Saliola M, et al. Association between low‐grade dissemi‐
nated intravascular coagulation and endotoxemia inpatients with liver cirrhosis. 
Gastroenterology. 1995;109:531‐539
Portal Vein Thrombosis in Patients with Liver Cirrhosis
http://dx.doi.org/10.5772/intechopen.68929
169
[29] Lin RS, Lee FY, Lee SD, et al. Endotoxemia in patients with chronic liver diseases: 
Relationship to severity of liver diseases, presence of esophageal varices, and hyperdy‐
namic circulation. Journal of Hepatology. 1995;22:165‐172
[30] Politoske D, Ralls P, Korula J. Portal vein thrombosis following endoscopic variceal 
sclerotherapy. Prospective controlled comparison in patients with cirrhosis. Digestive 
Diseases and Sciences. 1996;41:185‐190
[31] Li DX, Tang Z, Qiu XG. A study on the mechanism of acute portal vein thrombosis after 
pericardial devascularization with splenectomy for the treatment of portal hyperten‐
sion. Chinese Journal of Integrative Medicine. 2003;3:008
[32] Wu G, Li JS, Tao T, et al. Analysis on the risk factors of portal vein thrombosis after 
the operation in patients with portal hypertension. Journal of Chongqing Medical 
University. 2012;4:027
[33] Zhou GW, Li HW. Surgical therapy for portal hypertension in patients with cirrhosis 
in China: Present situation and prospects. Chinese Medical Journal. 2009;122:1483‐1485
[34] Senzolo M, Garcia‐Pagan JC. Incidence and natural course of portal vein thrombosis in 
cirrhosis. The American Journal of Gastroenterology. 2013;108:1807‐1808
[35] DeLeve LD, Valla DC, Garcia‐Tsao G, et al. Vascular disorders of the liver. Hepatology. 
2009;49(5):1729‐1764
[36] de Franchis R, Baveno VI. Expanding consensus in portal hypertension: Report of the 
Baveno VI consensus workshop: Stratifying risk and individualizing care for portal 
hypertension. Journal of Hepatology. 2015;63:743‐752
[37] Noronha Ferreira C, Seijo S, Plessier A, et al. Natural history and management ofe‐
sophagogastric varices in chronic noncirrhotic, nontumoral portal vein thrombosis. 
Hepatology. 2016;63:1640‐1650
[38] Bach AM, Hann LE, Brown KT, et al. Portal vein evaluation with US: Comparison to 
angiography combined with CT arterial portography. Radiology. 1996;201:149‐154
[39] Chawla Y, Kumar S. Portal venous flow in Budd–Chiari syndrome. Indian Journal of 
Gastroenterology: Official Journal of the Indian Society of Gastroenterology. 1998;17:37
[40] Danila M, Sporea I, Popescu A, et al. Portal vein thrombosis in liver cirrhosis—the 
added value of contrast enhanced ultrasonography. Journal of Medical Ultrasound. 
2016;18:218‐233
[41] Sabba C, Merkel C, Zoli M, et al. Interobserver and interequipment variability of echo‐
Doppler examination of the portal vein: Effect of a cooperative training program. 
Hepatology. 1995;21:428‐433
[42] Plessier A, Darwish‐Murad S, Hernandez‐Guerra M, et al. Acute portal vein throm‐
bosis unrelated to cirrhosis: A prospective multicenter follow‐up study. Hepatology. 
2010;51:210‐218
Liver Cirrhosis - Update and Current Challenges170
[43] Yerdel MA, Gunson B, Mirza D, et al. Portal vein thrombosis in adults undergoing liver 
transplantation: Risk factors, screening, management, and outcome. Transplantation. 
2000;69:1873‐1881
[44] Sarin SK, Philips CA, Kamath PS, et al. Toward a comprehensive new classification of 
portal vein thrombosis in patients with cirrhosis. Gastroenterology. 2016;151:574‐577, e3
[45] Piscaglia F, Gianstefani A, Ravaioli M, et al. Criteria for diagnosing benign portal vein 
thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for 
liver transplantation. Liver Transplantation. 2010;16:658‐667
[46] Francoz C, Belghiti J, Vilgrain V, et al. Splanchnic vein thrombosis in candidates for liver 
transplantation: Usefulness of screening and anticoagulation. Gut. 2005;54:691‐697
[47] Senzolo M, Sartori M, Rossetto V, et al. Prospective evaluation of anticoagulation and 
transjugular intrahepatic portosystemic shunt for the management of portal vein throm‐
bosis in cirrhosis. Liver International. 2012;32:919‐927
[48] Delgado MG, Seijo S, Yepes I, et al. Efficacy and safety of anticoagulation on patients 
with cirrhosis and portal vein thrombosis. Clinical Gastroenterology and Hepatology. 
2012;10:776‐783
[49] Huard G, Bilodeau M. Management of anticoagulation for portal vein thrombosis in 
individuals with cirrhosis: A systematic review. International Journal of Hepatology. 
2012;2012:672986
[50] Amitrano L, Guardascione MA, Menchise A, et al. Safety and efficacy of anticoagulation 
therapy with low molecular weight heparin for portal vein thrombosis in patients with 
liver cirrhosis. Journal of Clinical Gastroenterology. 2010;44:448‐451
[51] Girleanu I, Stanciu C, Cojocariu C, et al. Natural course of nonmalignant partial por‐
tal vein thrombosis in cirrhotic patients. Saudi Journal of Gastroenterology. 2014;20: 
288‐292
[52] Englesbe MJ, Kubus J, Muhammad W, et al. Portal vein thrombosis and survival in 
patients with cirrhosis. Liver Transplantation. 2010;16:83‐90
[53] Doenecke A, Tsui TY, Zuelke C, et al. Pre‐existent portal vein thrombosis in liver 
transplantation: Influence of preoperative disease severity. Clinical Transplantation. 
2010;24:48‐55
[54] Lisman T, Kamphuisen PW, Northup PG, Porte RJ. Established and new‐generation 
antithrombotic drugs in patients with cirrhosis –possibilities and caveats. Journal of 
Hepatology. 2013;59:358‐366
[55] Valla DC. Thrombosis and anticoagulation in liver disease. Hepatology. 2008;47:1384‐1393
[56] Han G, Qi X, He C, et al. Transjugular intrahepatic portosystemic shunt for portal 
vein thrombosis with symptomatic portal hypertension in liver cirrhosis. Journal of 
Hepatology. 2011;54:78‐88
Portal Vein Thrombosis in Patients with Liver Cirrhosis
http://dx.doi.org/10.5772/intechopen.68929
171
[57] Perarnau JM, Baju A, D<Alteroche L, et al. Feasibility and long term evolution of TIPS 
in cirrhotic patients with portal thrombosis. European Journal of Gastroenterology & 
Hepatology. 2010;22:1093‐1098
[58] Senzolo M, Burra P, Patch D, Burroughs AK. Tips for portal vein thrombosis in cirrhosis: 
Not only unblocking a pipe. Journal of Hepatology. 2011;55:945‐946
[59] Senzolo M, Tibbals J, Cholongitas E, et al. Transjugular intrahepatic portosystemic shunt 
for portal vein thrombosis with and without cavernous transformation. Alimentary 
Pharmacology & Therapeutics. 2006;23:767‐775
[60] De SA, Moscatelli R, Catalano C, et al. Systemic thrombolysis of portal vein thrombosis 
in cirrhotic patients: A pilot study. Digestive and Liver Disease. 2010;42:451‐455
[61] Llado L, Fabregat J, Castellote J, et al. Management of portal vein thrombosis in liver trans‐
plantation: Influence on morbidity and mortality. Clin Transplantation. 2007;21:716‐721
[62] Gimeno FA, Calvo J, Loinaz C, et al. Comparative analysis of the results of orthotopic liver 
transplantation in patients with and without portal vein thrombosis. Transplantation 
Proceedings. 2005;37:3899‐3903
[63] Rodriguez‐Castro KI, Porte RJ, Nadal E, et al. Management of nonneoplastic portal vein 
thrombosis in the setting of liver transplantation: A systematic review. Transplantation. 
2012;94:1145‐1153
[64] Ceulemans B, Aerts R, Monbaliu D, et al. Liver transplantation using cavoportal trans‐
position: An effective treatment in patients with complete splanchnic venous thrombo‐
sis. Transplantation Proceedings. 2005;37:1112
[65] Ponziani FR, Zocco MA, Campanale C, et al. Portal vein thrombosis: Insight into physio‐
pathology, diagnosis, and treatment. World Journal of Gastroenterology. 2010;16:143‐155
[66] Shaw Jr BW, Iwatsuki S, Bron K, Starzl TE. Portal vein grafts in hepatic transplantation. 
Surgery, Gynecology & Obstetrics. 1985;161:66‐68
Liver Cirrhosis - Update and Current Challenges172
